About: Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients
Creator	Desmet, Stefanie Lagrou, Katrien Ranst, Marc André, Emmanuel Brackenier, Anouk Depypere, Melissa Houben, Els Van Elslande, Jan Vermeersch, Pieter
source	Elsevier; Medline; PMC; WHO
abstract	OBJECTIVES: To evaluate the diagnostic performance of 7 rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2 in COVID-19 patients. METHODS: Specificity was evaluated in 103 samples collected before January 2020. Sensitivity and time to seropositivity was evaluated in samples from 94 patients with COVID-19 confirmed with PCR on nasopharyngeal swab. RESULTS: Specificity [confidence interval] of lateral flow assays (LFA) was ≥ 91.3% [84.0-95.5] for IgM, ≥ 90.3% [82.9-94.8] for IgG, and ≥ 85.4% [77.2-91.1] for the combination IgM OR IgG. Specificity of the ELISA was 96.1% [90.1-98.8] for IgG and only 73.8% [64.5-81.4] for IgA. Sensitivity 14-25 days after onset of symptoms was ≥ 92.1% [78.5-98.0] to 100% [95.7-100] for IgG LFA compared to 89.5% [75.3-96.4] for IgG ELISA. Positivity of IgM OR IgG for LFA resulted in a decrease in specificity compared to IgG alone without a gain in diagnostic performance except for VivaDiag. The results for IgM varied significantly between the LFA with an average overall agreement of only 70% compared to 89% for IgG. The average dynamic trend to seropositivity for IgM was not shorter than for IgG. At time of admission to the hospital, the sensitivity of LFA was <60%. CONCLUSIONS: Sensitivity for the detection IgG antibodies 14-25 days after onset of symptoms was ≥ 92.1% for all 7 LFA compared to 89.5% for the IgG ELISA. The results for IgM varied significantly and including IgM antibodies in addition to IgG for the interpretation of LFA did not improve the diagnostic performance.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2020.05.023
bibo:pmid	32473953
has license	no-cc
sha1sum (hex)	4d94e0394cf52d90d86ed534f84bf3d103815c5d
schema:url	https://doi.org/10.1016/j.cmi.2020.05.023
resource representing a document's title	Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients
has PubMed Central identifier	PMC7255746
has PubMed identifier	32473953
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:4d94e0394cf52d90d86ed534f84bf3d103815c5d#body_text
is schema:about of	named entity 'IgM' named entity 'LFA' named entity 'evaluate' named entity 'assays' named entity 'IgG' named entity 'antibody' named entity 'PERFORMANCE' named entity 'flow' named entity 'days' named entity 'varied' named entity 'seropositivity' named entity 'IgM' named entity 'compared' named entity 'IgG' named entity 'performance' named entity 'confirmed' named entity 'IgM' named entity 'max' named entity 'evaluated' named entity 'samples' named entity 'patients' named entity 'LFA' named entity 'IgA' named entity 'IgG' named entity 'lateral flow assays' named entity 'IgG' named entity 'IgM antibodies' named entity 'LFA' named entity '91.1' named entity 'LFA' named entity 'IgM' named entity 'IgG' named entity 'IgG' named entity 'LFA' named entity 'antibody tests' named entity 'COVID' named entity 'IgA' named entity 'IgG' named entity 'IgM' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'Wuhan' named entity 'ethics committee' named entity 'IgM' named entity 'coronavirus' named entity 'disease control' named entity 'Seroconversion' named entity 'antibody' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'IVD' named entity 'IgA' named entity 'IgG' named entity 'viral RNA' named entity 'IgG' named entity 'false-positive result' named entity 'seropositivity' named entity 'false-positive' named entity 'antibodies' named entity 'IgG' named entity 'Seropositivity' named entity 'IgG antibodies' named entity 'infection' named entity '7.9' named entity 'sensitivity and specificity' named entity 'IgG' named entity 'epidemiologic studies' named entity 'IgG' named entity 'IgG' named entity 'asymptomatic' named entity 'IgM' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software